Aktieanalys

Optomed Q4: Initial take – Sales came in lower than expected - Redeye

Redeye Publicerad: 15 Feb 08:55

Redeye provides an initial take on Optomed’s Q4 2023 report. Sales during the quarter amounted to EUR3.7m (EUR4.0m) compared to our sales estimate of EUR4.5m. Moreover, EBIT came in at EUR-1.3m (EUR-0.9m), and the cash position at the end of the period amounted to EUR7.1m. Overall, the results were lower than our expectations. However, we note that the additional data to the FDA has been submitted, meaning we have a major event in front of us. We will provide a more in-depth update shortly, where we expect to make some downward changes to our short-term estimates.

Länk till analysen i sin helhet: https://www.redeye.se/research/979718/optomed-q4-initial-take-sales-came-in-lower-than-expected?utm_source=finwire&utm_medium=RSS

Nyheter om Optomed

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!